{"gene":"SMAD4","run_date":"2026-06-10T07:46:35","timeline":{"discoveries":[{"year":1996,"finding":"DPC4/SMAD4 was identified as a candidate tumor suppressor gene at chromosome 18q21.1, with homozygous deletions in ~30% and intragenic mutations in ~20% of pancreatic carcinomas, implicating it in a TGF-β-like signaling pathway based on sequence similarity to Drosophila Mad.","method":"Homozygous deletion mapping, PCR/sequencing of tumor DNA","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genomic mapping with convergent homozygous deletions and intragenic mutations across 84 tumors; founding paper replicated across many subsequent studies","pmids":["8553070"],"is_preprint":false},{"year":1996,"finding":"DPC4/SMAD4 physically associates with Smad1 in response to BMP and with Smad2 in response to activin or TGF-β, forming regulated heteromeric complexes essential for mesoderm induction and antimitogenic responses in Xenopus embryos and breast epithelial cells.","method":"Co-immunoprecipitation, Xenopus embryo overexpression/dominant-negative assays, mammalian cell TGF-β response assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus functional rescue in two distinct systems (Xenopus and mammalian cells); replicated by multiple subsequent studies","pmids":["8893010"],"is_preprint":false},{"year":1997,"finding":"Smad4 is present in the activin-responsive factor (ARF) complex together with FAST-1 and Smad2; Smad4 stabilizes a ligand-stimulated Smad2-FAST-1 complex as an active DNA-binding factor. The FAST-1 C-terminal domain interacts with Smad2 (not Smad4 directly in yeast two-hybrid), but FAST-1 deletion mutants that cannot recruit Smad4 fail to associate with ARF.","method":"Co-immunoprecipitation (ligand-regulated), yeast two-hybrid, deletion mutagenesis, DNA-binding assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — reciprocal Co-IP, yeast two-hybrid, and deletion mutagenesis in single study with multiple orthogonal methods","pmids":["9288972"],"is_preprint":false},{"year":1997,"finding":"Smad4 contributes two distinct functions in TGF-β transcriptional complexes: its N-terminal (MH1) domain promotes DNA binding of the Smad2/Smad4/FAST-1 complex, while its C-terminal (MH2) domain provides a transcriptional activation function required for Smad1 or Smad2 to stimulate transcription. Smad4 is not required for nuclear translocation of Smad1/2 or for Smad2-FAST-1 association.","method":"Domain deletion and chimera constructs, transcriptional reporter assays, nuclear localization assays in mammalian cells","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — domain mapping with multiple deletion/chimera constructs plus functional transcriptional assays in single rigorous study","pmids":["9389648"],"is_preprint":false},{"year":1997,"finding":"Smad3 and Smad4/DPC4 undergo both homomeric and heteromeric interactions via their conserved C-terminal (MH2) domains; Smad4 homomeric interaction additionally requires the N-terminal domain. Cancer-associated mutations in the MH2 domain impair homo- and heteromeric associations and correlate with reduced signaling activity.","method":"Yeast two-hybrid, co-immunoprecipitation, transcriptional activation assays in yeast and mammalian cells, analysis of tumor-derived mutations","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — yeast two-hybrid plus co-IP plus functional assays with multiple mutants; single lab with orthogonal methods","pmids":["9111321"],"is_preprint":false},{"year":1998,"finding":"Smad4/DPC4 and CBP/p300 act as transcriptional coactivators for Smad3 in TGF-β-induced transcriptional activation; CBP associates with the C-terminus of Smad3 in a TGF-β-dependent manner, and this interaction requires Smad4. E1A expression, which blocks CBP function, inhibits TGF-β-induced transcription.","method":"Co-immunoprecipitation, transcriptional reporter assays, E1A inhibition experiments","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and functional transcriptional assays with multiple orthogonal approaches in single study","pmids":["9679060"],"is_preprint":false},{"year":1997,"finding":"A 47-amino acid deletion within the middle-linker region of Smad4 abolishes its ability to mediate TGF-β/activin signaling responses, while the N-terminal domain augments ligand-dependent activation, identifying a distinct ligand-response domain in the Smad4 linker.","method":"Smad4 deletion/chimera constructs, transcriptional reporter assays in Smad4-null cell line","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro functional domain mapping with multiple constructs but single lab, single study","pmids":["9153220"],"is_preprint":false},{"year":1998,"finding":"Homozygous Smad4 knockout mice die before embryonic day 7.5 and fail to gastrulate or form mesoderm. Tetraploid rescue experiments demonstrated that the gastrulation defect is non-cell-autonomous, arising secondary to abnormal visceral endoderm differentiation.","method":"Homologous recombination knockout, tetraploid aggregation rescue, histological and molecular marker analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with tetraploid rescue (orthogonal method), mesodermal marker analysis; independently replicated by Yang et al. 1998","pmids":["9420335"],"is_preprint":false},{"year":1998,"finding":"SMAD4 (truncating the C-terminal MH2 domain) homozygous knockout mice fail to undergo endoderm differentiation and mesoderm formation; blastocyst outgrowths show cellular proliferation defects, demonstrating that SMAD4-mediated signals are required for epiblast proliferation, egg-cylinder formation, and mesoderm induction.","method":"Homologous recombination knockout (exon 8 truncation), blastocyst outgrowth culture, histological and molecular marker analysis","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — independent replication of Smad4 knockout phenotype with distinct targeting strategy; replicated Sirard et al. findings","pmids":["9520423"],"is_preprint":false},{"year":1997,"finding":"DPC4/SMAD4 restoration in DPC4-deleted breast tumor cells (MDA-MB-468) reconstitutes TGF-β1-induced growth inhibition and transcriptional activation of a TGF-β sensitive reporter (3TPlux). A DPC4 splice variant lacking residues 223–301 fails to restore TGF-β responsiveness.","method":"Transfection/reconstitution in Smad4-null cell line, growth inhibition assays, transcriptional reporter assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reconstitution plus splice-variant characterization in Smad4-null cells; single lab, two orthogonal readouts","pmids":["9150356"],"is_preprint":false},{"year":2000,"finding":"Alanine-scanning mutagenesis of the MH1 domain mapped DNA-binding activity to residues L43–R135, demonstrating that the MH1 domain as a whole is structurally sensitive and that tumor-associated mutations outside the beta-hairpin motif inactivate Smad4 by disrupting DNA binding.","method":"Alanine scanning mutagenesis (20 individual mutations), in vitro DNA-binding assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic in vitro mutagenesis with DNA-binding assay; multiple mutants tested in single rigorous study","pmids":["10871368"],"is_preprint":false},{"year":2000,"finding":"Restoration of Smad4 in pancreatic carcinoma cells suppressed tumor formation in vivo without restoring TGF-β sensitivity; instead, Smad4 shifted angiogenic balance by decreasing VEGF expression and increasing thrombospondin-1 expression, reducing vascular density in tumors.","method":"Stable reconstitution in Smad4-null pancreatic cancer cells, in vivo nude mouse tumor assays, VEGF/thrombospondin-1 expression analysis","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reconstitution plus in vivo assay plus molecular target identification; single lab with multiple orthogonal methods","pmids":["10944227"],"is_preprint":false},{"year":1999,"finding":"In SW480.7 colon cancer cells, Smad4 loss is due to epigenetic silencing (not mutation); conditional re-expression of Smad4 alone failed to rescue TGF-β antiproliferative responses because co-existing hyperactive Ki-Ras inhibits Smad nuclear accumulation via MAPK phosphorylation. Co-expression of Smad4 with a Ras-phosphorylation-resistant Smad3 (but not wild-type Smad2, Smad3, APC, or TGF-β type II receptor) rescued the antiproliferative response.","method":"Ecdysone-inducible Smad4 expression, co-transfection epistasis analysis, cell proliferation assays, p21/c-myc gene response assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via co-transfection with multiple constructs plus functional proliferation readout; single lab, multiple orthogonal methods","pmids":["10559252"],"is_preprint":false},{"year":2004,"finding":"SCF(β-TrCP1) ubiquitin E3 ligase interacts with Smad4 (but not Smad2, and only indirectly with Smad3 through Smad4) and promotes Smad4 ubiquitination and proteasomal degradation; ectopic SCF(β-TrCP1) inhibited TGF-β-dependent transcriptional activity and cell cycle arrest, while siRNA knockdown of β-TrCP1 increased Smad4 protein levels.","method":"Yeast two-hybrid, co-immunoprecipitation, ubiquitination assays, siRNA knockdown, transcriptional reporter assays, cell cycle assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods including yeast two-hybrid, Co-IP, ubiquitination assay, siRNA, and functional readouts in single study","pmids":["14988407"],"is_preprint":false},{"year":2014,"finding":"Smad4 activity is directly regulated by phosphorylation: FGF activates MAPK which primes three sequential GSK3 phosphorylations in the Smad4 linker region, generating a β-TrCP-bound phosphodegron. Wnt signaling prevents these GSK3 phosphorylations and thereby potentiates TGF-β/Smad4 transcriptional activity. These phosphorylations regulate germ-layer specification in Xenopus embryos.","method":"Phosphosite mutagenesis, kinase assays (MAPK, GSK3), Xenopus embryo gain/loss-of-function experiments, β-TrCP binding assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — kinase assays, mutagenesis, and in vivo Xenopus validation with multiple orthogonal approaches in single study","pmids":["25373906"],"is_preprint":false},{"year":2019,"finding":"ALK tyrosine kinase directly phosphorylates SMAD4 at Tyr95; phospho-Y95 SMAD4 cannot bind DNA and fails to elicit TGF-β gene responses or tumor-suppressive responses. Chemical or genetic inhibition of ALK restores TGF-β responses in ALK-positive tumor cells.","method":"In vitro kinase assay, phospho-specific antibody, DNA-binding assay, transcriptional reporter assays, ALK inhibitor treatment and genetic knockdown","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase reconstitution plus mutagenesis plus functional DNA-binding and transcriptional readouts with pharmacological and genetic validation","pmids":["30664791"],"is_preprint":false},{"year":2017,"finding":"USP4 deubiquitinase removes inhibitory monoubiquitination from SMAD4, sustaining its activity in activin/BMP signaling. SMURF2 E3 ligase is recruited to SMAD4 upon ligand-induced R-SMAD-SMAD4 complex formation to add monoubiquitin. The negative regulator c-SKI inhibits SMAD4 monoubiquitination. USP4 depletion in mouse ESCs increased monoubiquitinated SMAD4 and impaired BMP/activin-induced cell fate changes.","method":"Ubiquitination assays, co-immunoprecipitation, USP4 knockdown in mouse ESCs, zebrafish morpholino knockdown with rescue experiments","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — biochemical ubiquitination assays plus genetic loss-of-function in ESCs and zebrafish with functional rescue; multiple orthogonal methods","pmids":["28468752"],"is_preprint":false},{"year":2019,"finding":"USP10 deubiquitinase directly interacts with Smad4 and stabilizes it by removing proteolytic ubiquitination, thereby activating TGF-β signaling and promoting HCC metastasis. Suppression of USP10 reduced Smad4 protein levels and inhibited HCC cell migration; reconstitution of Smad4 rescued this defect.","method":"siRNA library screen, co-immunoprecipitation, ubiquitination assays, shRNA knockdown, Smad4 reconstitution, migration assays","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional screen plus Co-IP plus ubiquitination assay plus rescue experiment; single lab, multiple methods","pmids":["31721429"],"is_preprint":false},{"year":2020,"finding":"Wip1 phosphatase selectively binds and dephosphorylates Smad4 at Thr277 (a key MAPK phosphorylation site), regulating Smad4 nuclear accumulation and protein half-life. Wip1 restrains TGF-β-induced growth arrest, migration, and invasion, and inhibits Smad4 antimitogenic activity in human cells and mesoderm formation in Xenopus.","method":"Co-immunoprecipitation, phosphatase assay, phospho-specific antibody detection, Xenopus gain/loss-of-function, cell migration/invasion assays","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical phosphatase assay plus Co-IP plus in vivo Xenopus validation; single lab, multiple orthogonal methods","pmids":["32103600"],"is_preprint":false},{"year":2023,"finding":"PRMT5 interacts with SMAD4 under TGF-β1 treatment and methylates SMAD4 at R361; this methylation is required for SMAD complex formation and nuclear import. SMAD4 R361 mutation abolishes PRMT5-induced EMT and colorectal cancer metastasis.","method":"Mass spectrometry, co-immunoprecipitation, immunofluorescence, methylation-specific assays, SMAD4 R361 mutant functional studies","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry identification plus Co-IP plus functional mutagenesis; single lab with multiple orthogonal methods","pmids":["36991117"],"is_preprint":false},{"year":2023,"finding":"SFPQ, a prion-like RNA-binding protein, physically sequesters Smad4 in liquid-liquid phase separation (LLPS) condensates via its prion-like domain (PrLD), excluding Smad4 from Smad complexes and chromatin, thereby suppressing TGF-β transcriptional responses. SFPQ deficiency or abolition of phase separation activity renders cells hypersensitive to TGF-β.","method":"Co-immunoprecipitation, LLPS assays, ChIP, transcriptional reporter assays, SFPQ phase-separation mutants","journal":"Developmental cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical LLPS characterization plus Co-IP plus chromatin occupancy assays; single lab, multiple orthogonal methods","pmids":["38103553"],"is_preprint":false},{"year":2018,"finding":"Endothelial-specific loss of Smad4 in mice causes arteriovenous malformation (AVM) formation. Mechanistically, BMP9 signaling antagonizes flow-induced AKT activation in an ALK1- and SMAD4-dependent manner; Smad4-deficient endothelial cells display increased PI3K/AKT signaling. BMP9-induced SMAD4 inhibits CK2 (casein kinase 2) transcription, limiting PTEN phosphorylation and AKT activation. PI3K inhibition or endothelial Akt1 deletion rescues AVMs in Smad4-deficient mice.","method":"Tamoxifen-inducible endothelial-specific Smad4 knockout mice, pharmacological PI3K inhibition, Akt1 genetic rescue, CK2 inhibition, AKT phosphorylation assays","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional knockout with multiple genetic and pharmacological rescue experiments; single lab with multiple orthogonal approaches","pmids":["29976569"],"is_preprint":false},{"year":2019,"finding":"SMAD4 and HNF4 (HNF4A and HNF4G) function via a reinforcing feed-forward loop in the intestinal epithelium: SMAD4 and HNF4 activate each other's expression and co-bind regulatory elements of differentiation genes to promote and stabilize enterocyte cell identity. Disruption of this HNF4-SMAD4 module results in loss of enterocyte fate in favor of progenitor and secretory cell lineages.","method":"Conditional double knockout (HNF4A/G), SMAD4 conditional knockout, ChIP-seq cistromic analysis, transcriptomic profiling, intestinal organoid assays","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — combined genetic knockout with ChIP-seq co-binding data and transcriptomics; single lab with multiple orthogonal methods","pmids":["30988513"],"is_preprint":false},{"year":2014,"finding":"SMAD4 is absolutely required for normal FSH (Fshb) synthesis in vivo; conditional Smad4 deletion in gonadotropes abolishes FSH synthesis. Combined deletion of Smad4 and its DNA-binding cofactor FOXL2 in gonadotropes results in near-complete absence of FSH and female sterility, phenocopying Fshb-knockout mice, establishing SMAD4 and FOXL2 as essential co-regulators of Fshb transcription.","method":"Conditional gonadotrope-specific Smad4 and Foxl2 single/double knockout mice, FSH measurement, fertility assessment","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean conditional knockout with quantitative FSH measurement and genetic epistasis; single lab, multiple knockout combinations","pmids":["24739304"],"is_preprint":false},{"year":2020,"finding":"Under hyperglycemic conditions, Smad4 localizes to mitochondria in podocytes, directly binds the glycolytic enzyme PKM2 (reducing its active tetrameric form) and interacts with ATPIF1 (reducing its degradation), resulting in reduced glycolysis and oxidative phosphorylation and increased ROS production, contributing to diabetic nephropathy.","method":"Conditional podocyte-specific Smad4 knockout mice, subcellular fractionation, co-immunoprecipitation, PKM2 activity assays, metabolic flux measurements","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional knockout plus Co-IP plus enzymatic activity assay; single lab with multiple methods but novel/unusual finding","pmids":["31916354"],"is_preprint":false},{"year":2003,"finding":"Mammary epithelium-specific Smad4 deletion causes squamous cell carcinoma and mammary abscesses via transdifferentiation. Loss of Smad4 leads to β-catenin accumulation at onset of transdifferentiation; TGF-β1 degrades β-catenin in cultured mammary epithelial cells, but this action is blocked in the absence of Smad4, implicating Smad4 in suppressing Wnt/β-catenin signaling during cell fate maintenance.","method":"Cre-loxP conditional mammary-specific Smad4 knockout, immunohistochemistry for β-catenin, TGF-β1 treatment assays in cultured cells","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional knockout plus mechanistic cell culture validation; single lab with multiple approaches","pmids":["14597578"],"is_preprint":false},{"year":2021,"finding":"SMAD4 represses FOSL1 expression; in pancreatic cancer cells, SMAD4 loss leads to FOSL1 upregulation that is sufficient to drive metastatic colonization to the lung, identified by an in vivo CRISPR/genetic screen.","method":"Isogenic cell lines with/without SMAD4, in vivo functional screen, transcriptomic analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo screen plus isogenic cell comparison; single lab, functional validation limited to screen confirmation","pmids":["34320363"],"is_preprint":false},{"year":2000,"finding":"DPC4 inactivation in pancreatic cancer occurs late in neoplastic progression: all PanIN-1A, PanIN-1B, and PanIN-2 lesions retained Dpc4 expression, while 31% of PanIN-3 (carcinoma in situ) lesions lost it, demonstrating stage-specific loss of the tumor suppressor.","method":"Immunohistochemistry for Dpc4 protein in 188 pancreatic intraepithelial neoplasias (PanINs) correlated with genetic status","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic IHC correlated with genetic status across large series; replicated across multiple pancreatic cancer studies","pmids":["10766191"],"is_preprint":false},{"year":2004,"finding":"Missense mutations in SMAD4 are concentrated in the MH2 domain (77%), with a mutation cluster region (MCR) at codons 330–370. Mutations outside the MCR correlate with loss of Madh4 protein (suggesting degradation), while MCR mutations retain nuclear protein, indicating that most missense mutations inactivate Smad4 via protein destabilization/degradation rather than direct functional disruption.","method":"Sequence analysis of tumors, immunohistochemistry for Madh4 protein in archival cancers with known missense mutations","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — systematic mutation mapping with IHC correlation across multiple tumor types; functional inference from protein expression pattern","pmids":["15014009"],"is_preprint":false},{"year":2015,"finding":"Combined loss of PTEN and SMAD4 in mouse airway epithelium leads to metastatic adenosquamous lung tumors through ELF3 and ErbB2 pathway activation due to decreased ERRFI1 expression. Combinatorial inhibition of ErbB2 and Akt attenuates tumor progression and invasion.","method":"Conditional Pten/Smad4 double knockout mouse model, comparative transcriptomics, in vivo cistromics, pharmacological inhibition","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — double conditional knockout with transcriptomic and cistromic analysis plus pharmacological rescue; single lab, multiple orthogonal methods","pmids":["25753424"],"is_preprint":false},{"year":2019,"finding":"SMAD4 directly binds the FZD4 promoter as a transcription factor to activate FZD4 transcription in granulosa cells, and also promotes FZD4 expression indirectly via induction of a lncRNA (SDNOR) that sponges miR-29c (which would otherwise degrade FZD4 mRNA), establishing a SMAD4-FZD4 axis that activates Wnt signaling to regulate granulosa cell apoptosis.","method":"ChIP (SMAD4 binding to FZD4 promoter), luciferase reporter assays, SMAD4 overexpression/knockdown, miRNA sponge assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus luciferase plus functional knockdown; single lab with multiple methods","pmids":["32415058"],"is_preprint":false},{"year":2021,"finding":"Smad4 regulates adult astrocyte proliferation in the diencephalon; Smad4 deletion in diencephalic astrocytes reduces in vivo proliferation and in vitro neurosphere formation, identifying Smad4 as a key regulator of adult astrogenesis in this brain region.","method":"Single-cell RNA-seq, MACS isolation of astrocytes, conditional Smad4 deletion, BrdU/clonal analysis, neurosphere assays","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional knockout with in vivo clonal analysis and in vitro neurosphere assay; single lab, multiple methods","pmids":["34549820"],"is_preprint":false}],"current_model":"SMAD4/DPC4 functions as the central co-SMAD in TGF-β superfamily signaling: upon ligand stimulation, it forms heteromeric complexes with receptor-activated SMADs (R-SMADs such as Smad1, Smad2, Smad3), translocates to the nucleus, and activates transcription via its MH1 DNA-binding domain and MH2 transcriptional activation domain, in cooperation with co-activators such as CBP/p300 and transcription factors such as FAST-1, HNF4, and FOXL2; its activity is dynamically regulated by multiple post-translational modifications including GSK3/MAPK-primed phosphodegron formation (targeting it for SCF(β-TrCP1)-mediated ubiquitin-proteasomal degradation), SMURF2-mediated inhibitory monoubiquitination (reversed by USP4 and USP10 deubiquitinases), Wip1-mediated Thr277 dephosphorylation, PRMT5-mediated R361 methylation (required for SMAD complex assembly), and ALK-mediated Y95 phosphorylation (which blocks DNA binding); SFPQ can sequester SMAD4 in phase-separated condensates to suppress its transcriptional activity; in addition to canonical transcriptional roles, SMAD4 suppresses angiogenesis (by decreasing VEGF and increasing thrombospondin-1), regulates the PI3K/AKT/CK2 axis in endothelium to prevent arteriovenous malformations, and controls intestinal differentiation via a reinforcing feed-forward loop with HNF4, while its loss in various epithelial contexts promotes tumor progression through de-repression of VEGF, FOSL1, CCL20, and WNT/β-catenin-driven dedifferentiation."},"narrative":{"mechanistic_narrative":"SMAD4 (DPC4) is the central co-SMAD that transduces TGF-β superfamily signals into transcriptional responses and acts as a tumor suppressor first identified through homozygous deletion and intragenic mutation at chromosome 18q21.1 in pancreatic carcinoma [PMID:8553070]. Upon ligand stimulation it forms regulated heteromeric complexes with receptor-activated R-SMADs — Smad1 in response to BMP and Smad2 in response to activin/TGF-β — interactions that drive mesoderm induction and antimitogenic responses [PMID:8893010]. Within these complexes SMAD4 contributes two separable functions: its N-terminal MH1 domain promotes DNA binding while its C-terminal MH2 domain supplies a transcriptional activation function, with the MH2 domain also mediating the homo- and heteromeric associations that cancer-associated mutations disrupt [PMID:9389648, PMID:9111321, PMID:10871368]. SMAD4 stabilizes DNA-binding transcription-factor complexes (e.g., the Smad2–FAST-1 ARF complex) and recruits the coactivator CBP/p300 to activate TGF-β-responsive transcription [PMID:9288972, PMID:9679060]. Genetically it is essential for early development, as Smad4-null mice fail to gastrulate and form mesoderm owing to defective visceral endoderm and epiblast proliferation [PMID:9420335, PMID:9520423]. SMAD4 activity is tuned by a dense layer of post-translational control: MAPK/GSK3-primed linker phosphorylation generates a β-TrCP phosphodegron targeting SMAD4 for SCF(β-TrCP1)-mediated proteasomal degradation [PMID:14988407, PMID:25373906]; SMURF2-mediated inhibitory monoubiquitination is reversed by the deubiquitinases USP4 and USP10 [PMID:28468752, PMID:31721429]; Wip1 dephosphorylates Thr277 to limit nuclear accumulation [PMID:32103600]; PRMT5-mediated R361 methylation is required for SMAD complex assembly and nuclear import [PMID:36991117]; ALK-mediated Tyr95 phosphorylation blocks DNA binding [PMID:30664791]; and SFPQ sequesters SMAD4 in phase-separated condensates to exclude it from chromatin [PMID:38103553]. Beyond canonical transcription, SMAD4 enforces tissue identity and suppresses tumor progression — shifting the angiogenic balance by repressing VEGF and inducing thrombospondin-1 [PMID:10944227], restraining endothelial PI3K/AKT signaling through CK2 to prevent arteriovenous malformations [PMID:29976569], stabilizing enterocyte identity via a reinforcing feed-forward loop with HNF4 [PMID:30988513], and suppressing Wnt/β-catenin-driven dedifferentiation and metastatic effectors such as FOSL1 [PMID:14597578, PMID:34320363]. Germline/somatic loss in epithelial contexts thus de-represses pro-tumorigenic programs, with DPC4 inactivation occurring late in pancreatic neoplastic progression [PMID:10766191].","teleology":[{"year":1996,"claim":"Established SMAD4/DPC4 as a candidate tumor suppressor and placed it in a TGF-β-like pathway, answering where the gene sits in cancer genetics.","evidence":"Homozygous deletion mapping and sequencing of pancreatic tumor DNA at 18q21.1","pmids":["8553070"],"confidence":"High","gaps":["Did not define the biochemical activity of the protein","Pathway link inferred from sequence similarity to Mad rather than direct biochemistry"]},{"year":1996,"claim":"Defined SMAD4 as a ligand-regulated partner of multiple R-SMADs, answering how it couples to distinct TGF-β superfamily ligands.","evidence":"Co-immunoprecipitation plus Xenopus and mammalian functional assays","pmids":["8893010"],"confidence":"High","gaps":["Did not map the domains mediating each interaction","Did not establish nuclear vs cytoplasmic site of complex assembly"]},{"year":1997,"claim":"Resolved the molecular logic of SMAD4 within transcriptional complexes — MH1 for DNA binding, MH2 for activation and oligomerization — explaining why cancer mutations cluster in MH2.","evidence":"Domain deletion/chimera constructs, yeast two-hybrid, ARF complex reconstitution, reporter assays","pmids":["9288972","9389648","9111321","9153220"],"confidence":"High","gaps":["Functional contribution of the linker region characterized in only a single study","Did not provide atomic structure of the complexes"]},{"year":1997,"claim":"Demonstrated that SMAD4 re-expression restores TGF-β growth inhibition in SMAD4-null tumor cells, establishing causal tumor-suppressive function.","evidence":"Reconstitution in MDA-MB-468 cells with growth inhibition and reporter readouts","pmids":["9150356"],"confidence":"Medium","gaps":["Single cell line","Did not separate growth-arrest from later angiogenic functions"]},{"year":1998,"claim":"Showed SMAD4 is essential for gastrulation and mesoderm formation, defining its non-redundant developmental requirement.","evidence":"Two independent knockout mouse lines with tetraploid rescue and blastocyst outgrowth analysis","pmids":["9420335","9520423"],"confidence":"High","gaps":["Lethality precludes analysis of later tissue-specific roles","Did not identify the downstream developmental targets"]},{"year":1998,"claim":"Identified CBP/p300 as the coactivator SMAD4 recruits, answering how the complex drives transcription.","evidence":"Co-IP, reporter assays, and E1A inhibition","pmids":["9679060"],"confidence":"High","gaps":["Did not map promoter-specific recruitment","Did not address coactivator competition in vivo"]},{"year":2000,"claim":"Revealed a transcription-independent tumor-suppressive output — angiogenesis suppression via VEGF down and thrombospondin-1 up — broadening SMAD4 function beyond growth arrest.","evidence":"Stable reconstitution in pancreatic cancer cells with in vivo nude-mouse tumor and expression analysis","pmids":["10944227"],"confidence":"High","gaps":["Mechanism of VEGF/TSP-1 regulation not resolved at promoter level","Restoration occurred without restoring TGF-β sensitivity"]},{"year":2000,"claim":"Mapped MH1 DNA-binding determinants and showed tumor mutations inactivate SMAD4 by disrupting DNA binding or protein stability, linking genotype to molecular defect.","evidence":"Alanine-scanning mutagenesis with in vitro DNA-binding assays; later IHC mutation mapping","pmids":["10871368","15014009"],"confidence":"High","gaps":["Stability-based inactivation is inferred from protein levels rather than direct turnover measurement","MH1 mutation effects assessed in vitro"]},{"year":2000,"claim":"Established the timing of DPC4 loss in pancreatic neoplasia, answering when in tumor evolution the suppressor is inactivated.","evidence":"IHC across 188 PanIN lesions correlated with genetic status","pmids":["10766191"],"confidence":"High","gaps":["Correlative; does not prove loss drives progression","Restricted to pancreatic lesions"]},{"year":2003,"claim":"Showed that SMAD4 maintains epithelial identity by suppressing Wnt/β-catenin, explaining transdifferentiation phenotypes upon loss.","evidence":"Mammary-specific conditional knockout with β-catenin IHC and TGF-β1 degradation assays","pmids":["14597578"],"confidence":"Medium","gaps":["Mechanism linking SMAD4 to β-catenin degradation not biochemically defined","Single tissue context"]},{"year":2004,"claim":"Identified SCF(β-TrCP1) as a SMAD4 E3 ligase, establishing proteasomal control of SMAD4 abundance and signaling output.","evidence":"Yeast two-hybrid, Co-IP, ubiquitination assays, siRNA, functional readouts","pmids":["14988407"],"confidence":"High","gaps":["Did not define the degron recognized by β-TrCP","Upstream priming kinases unidentified at this stage"]},{"year":2014,"claim":"Defined the MAPK/GSK3-primed phosphodegron and its antagonism by Wnt, integrating SMAD4 stability into broader signaling crosstalk.","evidence":"Phosphosite mutagenesis, kinase assays, β-TrCP binding, Xenopus gain/loss-of-function","pmids":["25373906"],"confidence":"High","gaps":["In vivo relevance shown in Xenopus; mammalian developmental role not addressed","Did not quantify endogenous degradation kinetics"]},{"year":2014,"claim":"Demonstrated an essential SMAD4–FOXL2 partnership for FSH synthesis, establishing a tissue-specific transcriptional cofactor relationship.","evidence":"Gonadotrope-specific single and double conditional knockouts with FSH and fertility measurement","pmids":["24739304"],"confidence":"High","gaps":["Direct co-occupancy of the Fshb promoter not shown here","Limited to gonadotrope lineage"]},{"year":2015,"claim":"Showed SMAD4 loss cooperates with PTEN loss to drive metastatic lung tumors via ERRFI1/ErbB2 signaling, expanding its suppressor function to a new epithelium.","evidence":"Pten/Smad4 double knockout mice with transcriptomics, cistromics, pharmacological inhibition","pmids":["25753424"],"confidence":"Medium","gaps":["Combinatorial context required; single-gene SMAD4 effect not isolated","Direct SMAD4 regulation of ERRFI1 not fully resolved"]},{"year":2017,"claim":"Established that reversible SMURF2 monoubiquitination, opposed by USP4, tunes SMAD4 activity in stem-cell fate decisions.","evidence":"Ubiquitination assays, Co-IP, USP4 knockdown in ESCs, zebrafish morpholino rescue","pmids":["28468752"],"confidence":"High","gaps":["Monoubiquitination site on SMAD4 not specified here","Interplay with degradative ubiquitination not addressed"]},{"year":2018,"claim":"Defined an endothelial-specific SMAD4 function preventing arteriovenous malformations via BMP9/ALK1 restraint of PI3K/AKT through CK2, distinguishing a vascular role from canonical transcription.","evidence":"Endothelial-specific inducible knockout with PI3K inhibition, Akt1 deletion, and CK2 manipulation rescues","pmids":["29976569"],"confidence":"High","gaps":["Direct transcriptional repression of CK2 by SMAD4 inferred","Human AVM relevance not tested in this study"]},{"year":2019,"claim":"Identified ALK-mediated Tyr95 phosphorylation as a DNA-binding-blocking modification, providing a druggable route to restore SMAD4 tumor suppression.","evidence":"In vitro kinase assay, phospho-specific antibody, DNA-binding/reporter assays, ALK inhibition","pmids":["30664791"],"confidence":"High","gaps":["Prevalence of Y95 phosphorylation across tumor types not quantified","Structural basis of DNA-binding loss not solved"]},{"year":2019,"claim":"Showed USP10 deubiquitinates and stabilizes SMAD4 to promote HCC metastasis, illustrating context-dependent oncogenic output of SMAD4 stabilization.","evidence":"siRNA screen, Co-IP, ubiquitination assays, knockdown with SMAD4 rescue, migration assays","pmids":["31721429"],"confidence":"Medium","gaps":["Single cancer context; reciprocal to suppressor role","Ubiquitin linkage type not defined"]},{"year":2019,"claim":"Defined a SMAD4–HNF4 feed-forward loop that stabilizes enterocyte identity, explaining how SMAD4 enforces lineage fate.","evidence":"Conditional knockouts, ChIP-seq co-binding, transcriptomics, organoid assays","pmids":["30988513"],"confidence":"High","gaps":["Did not address upstream ligand control of the loop","Tumor-suppressive consequence in intestine not directly tested"]},{"year":2019,"claim":"Identified a SMAD4–FZD4 axis (direct promoter binding plus lncRNA-mediated regulation) coupling SMAD4 to Wnt activation in granulosa cells.","evidence":"ChIP, luciferase, overexpression/knockdown, miRNA sponge assays","pmids":["32415058"],"confidence":"Medium","gaps":["Single cell-type context","lncRNA/miR-29c module not validated in vivo"]},{"year":2020,"claim":"Showed Wip1 dephosphorylates SMAD4 at Thr277 to restrain its nuclear accumulation and antimitogenic activity, adding phosphatase control to the regulatory layer.","evidence":"Co-IP, phosphatase assay, phospho-specific detection, Xenopus and migration/invasion assays","pmids":["32103600"],"confidence":"Medium","gaps":["Single lab","Relationship of Thr277 to the GSK3/β-TrCP degron not integrated"]},{"year":2020,"claim":"Revealed a non-transcriptional mitochondrial SMAD4 function binding PKM2 and ATPIF1 to alter metabolism in diabetic nephropathy.","evidence":"Podocyte-specific knockout, subcellular fractionation, Co-IP, enzyme activity and metabolic flux assays","pmids":["31916354"],"confidence":"Medium","gaps":["Unusual mitochondrial localization not independently confirmed","Mechanism of SMAD4 mitochondrial import unknown"]},{"year":2021,"claim":"Identified FOSL1 de-repression as a sufficient driver of metastasis upon SMAD4 loss in pancreatic cancer.","evidence":"Isogenic SMAD4 cells, in vivo CRISPR/genetic screen, transcriptomics","pmids":["34320363"],"confidence":"Medium","gaps":["Validation limited to screen confirmation","Direct vs indirect FOSL1 repression not resolved"]},{"year":2021,"claim":"Established SMAD4 as a regulator of adult astrocyte proliferation, extending its role to CNS lineage maintenance.","evidence":"scRNA-seq, conditional deletion, BrdU/clonal analysis, neurosphere assays","pmids":["34549820"],"confidence":"Medium","gaps":["Downstream transcriptional program in astrocytes unknown","Single brain region"]},{"year":2023,"claim":"Defined PRMT5-mediated R361 methylation as a requirement for SMAD complex assembly and nuclear import, adding methylation to SMAD4 control and linking it to EMT/metastasis.","evidence":"Mass spectrometry, Co-IP, immunofluorescence, R361 mutant functional studies","pmids":["36991117"],"confidence":"Medium","gaps":["Single lab","Interplay with phosphorylation/ubiquitination not addressed"]},{"year":2023,"claim":"Showed SFPQ sequesters SMAD4 in phase-separated condensates to suppress its activity, introducing biomolecular condensation as a regulatory mechanism.","evidence":"Co-IP, LLPS assays, ChIP, reporter assays, SFPQ phase-separation mutants","pmids":["38103553"],"confidence":"Medium","gaps":["Physiological/in vivo relevance of condensate sequestration not established","Single study"]},{"year":null,"claim":"How the layered post-translational marks (phospho-degron, mono-ubiquitination, methylation, tyrosine phosphorylation) and condensate sequestration are coordinated to set SMAD4 output in a given tissue remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated model reconciling competing modifications","Tissue-specific selectivity of regulators not mapped","No structural model of the modified, complex-assembled SMAD4"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,10,15,30]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,5,22,30]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,18,19]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,14]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,5,22]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,8,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,11,26]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[13,16,19]}],"complexes":["SMAD2/SMAD4/FAST-1 (ARF) complex","R-SMAD/SMAD4 heteromeric complex"],"partners":["SMAD2","SMAD3","SMAD1","FAST-1","CBP/P300","HNF4A","FOXL2","SFPQ"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13485","full_name":"SMAD family member 4","aliases":["Deletion target in pancreatic carcinoma 4","Mothers against decapentaplegic homolog 4","MAD homolog 4","Mothers against DPP homolog 4"],"length_aa":552,"mass_kda":60.4,"function":"In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (By similarity). Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling (PubMed:25514493). Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q13485/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMAD4","classification":"Not Classified","n_dependent_lines":37,"n_total_lines":1208,"dependency_fraction":0.030629139072847682},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SMAD4","total_profiled":1310},"omim":[{"mim_id":"620997","title":"SEMAPHORIN 3G; SEMA3G","url":"https://www.omim.org/entry/620997"},{"mim_id":"618976","title":"MYOCARDIN-INDUCED SMOOTH MUSCLE LONG NONCODING RNA, INDUCER OF DIFFERENTIATION; MYOSLID","url":"https://www.omim.org/entry/618976"},{"mim_id":"618489","title":"BROMODOMAIN-CONTAINING PROTEIN 7; BRD7","url":"https://www.omim.org/entry/618489"},{"mim_id":"615886","title":"SCAFFOLDING CK1-ANCHORING PROTEIN G; SACK1G","url":"https://www.omim.org/entry/615886"},{"mim_id":"615708","title":"ZINC FINGER PROTEIN 451; ZNF451","url":"https://www.omim.org/entry/615708"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Centrosome","reliability":"Supported"},{"location":"Basal body","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SMAD4"},"hgnc":{"alias_symbol":["DPC4"],"prev_symbol":["MADH4"]},"alphafold":{"accession":"Q13485","domains":[{"cath_id":"3.90.520.10","chopping":"15-134","consensus_level":"high","plddt":93.2901,"start":15,"end":134},{"cath_id":"2.60.200.10","chopping":"287-294_314-441_493-539","consensus_level":"high","plddt":95.9473,"start":287,"end":539}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13485","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13485-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13485-F1-predicted_aligned_error_v6.png","plddt_mean":73.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMAD4","jax_strain_url":"https://www.jax.org/strain/search?query=SMAD4"},"sequence":{"accession":"Q13485","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13485.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13485/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13485"}},"corpus_meta":[{"pmid":"8553070","id":"PMC_8553070","title":"DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8553070","citation_count":2106,"is_preprint":false},{"pmid":"8893010","id":"PMC_8893010","title":"Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8893010","citation_count":813,"is_preprint":false},{"pmid":"9582123","id":"PMC_9582123","title":"Mutations in the SMAD4/DPC4 gene in juvenile polyposis.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9582123","citation_count":695,"is_preprint":false},{"pmid":"8653691","id":"PMC_8653691","title":"DPC4 gene in various tumor types.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8653691","citation_count":631,"is_preprint":false},{"pmid":"15031030","id":"PMC_15031030","title":"A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).","date":"2004","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15031030","citation_count":561,"is_preprint":false},{"pmid":"9288972","id":"PMC_9288972","title":"Smad4 and FAST-1 in the assembly of activin-responsive factor.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9288972","citation_count":496,"is_preprint":false},{"pmid":"29483830","id":"PMC_29483830","title":"The role of TGF-β/SMAD4 signaling in cancer.","date":"2018","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29483830","citation_count":486,"is_preprint":false},{"pmid":"10766191","id":"PMC_10766191","title":"Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10766191","citation_count":477,"is_preprint":false},{"pmid":"9679060","id":"PMC_9679060","title":"The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9679060","citation_count":446,"is_preprint":false},{"pmid":"9420335","id":"PMC_9420335","title":"The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9420335","citation_count":401,"is_preprint":false},{"pmid":"9389648","id":"PMC_9389648","title":"Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9389648","citation_count":393,"is_preprint":false},{"pmid":"12097290","id":"PMC_12097290","title":"Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12097290","citation_count":337,"is_preprint":false},{"pmid":"9520423","id":"PMC_9520423","title":"The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520423","citation_count":289,"is_preprint":false},{"pmid":"11787853","id":"PMC_11787853","title":"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.","date":"2001","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11787853","citation_count":284,"is_preprint":false},{"pmid":"10623651","id":"PMC_10623651","title":"Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.","date":"2000","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10623651","citation_count":271,"is_preprint":false},{"pmid":"10944227","id":"PMC_10944227","title":"Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10944227","citation_count":223,"is_preprint":false},{"pmid":"8898652","id":"PMC_8898652","title":"Somatic alterations of the DPC4 gene in human colorectal cancers in vivo.","date":"1996","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/8898652","citation_count":204,"is_preprint":false},{"pmid":"15235019","id":"PMC_15235019","title":"The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations.","date":"2004","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15235019","citation_count":199,"is_preprint":false},{"pmid":"9111321","id":"PMC_9111321","title":"Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9111321","citation_count":189,"is_preprint":false},{"pmid":"12821112","id":"PMC_12821112","title":"Role of Smad4 (DPC4) inactivation in human cancer.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12821112","citation_count":179,"is_preprint":false},{"pmid":"12010891","id":"PMC_12010891","title":"Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma.","date":"2002","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/12010891","citation_count":150,"is_preprint":false},{"pmid":"10626800","id":"PMC_10626800","title":"Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10626800","citation_count":149,"is_preprint":false},{"pmid":"12454109","id":"PMC_12454109","title":"DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.","date":"2002","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12454109","citation_count":147,"is_preprint":false},{"pmid":"8653689","id":"PMC_8653689","title":"DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8653689","citation_count":144,"is_preprint":false},{"pmid":"10490821","id":"PMC_10490821","title":"Smad2 and Smad4 gene mutations in hepatocellular carcinoma.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10490821","citation_count":137,"is_preprint":false},{"pmid":"9150356","id":"PMC_9150356","title":"DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9150356","citation_count":136,"is_preprint":false},{"pmid":"9153220","id":"PMC_9153220","title":"Characterization of functional domains within Smad4/DPC4.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9153220","citation_count":133,"is_preprint":false},{"pmid":"12136244","id":"PMC_12136244","title":"Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers.","date":"2002","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12136244","citation_count":128,"is_preprint":false},{"pmid":"10559252","id":"PMC_10559252","title":"Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10559252","citation_count":126,"is_preprint":false},{"pmid":"30988513","id":"PMC_30988513","title":"A reinforcing HNF4-SMAD4 feed-forward module stabilizes enterocyte identity.","date":"2019","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30988513","citation_count":125,"is_preprint":false},{"pmid":"20087440","id":"PMC_20087440","title":"Smad4-mediated TGF-beta signaling in tumorigenesis.","date":"2010","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20087440","citation_count":122,"is_preprint":false},{"pmid":"12077092","id":"PMC_12077092","title":"Frequent loss of SMAD4/DPC4 protein in colorectal cancers.","date":"2002","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/12077092","citation_count":117,"is_preprint":false},{"pmid":"29976569","id":"PMC_29976569","title":"SMAD4 Prevents Flow Induced Arteriovenous Malformations by Inhibiting Casein Kinase 2.","date":"2018","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/29976569","citation_count":104,"is_preprint":false},{"pmid":"21112326","id":"PMC_21112326","title":"MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21112326","citation_count":97,"is_preprint":false},{"pmid":"10327057","id":"PMC_10327057","title":"Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10327057","citation_count":94,"is_preprint":false},{"pmid":"11021814","id":"PMC_11021814","title":"Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease.","date":"2000","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11021814","citation_count":92,"is_preprint":false},{"pmid":"15042598","id":"PMC_15042598","title":"Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression.","date":"2004","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15042598","citation_count":92,"is_preprint":false},{"pmid":"14988407","id":"PMC_14988407","title":"Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14988407","citation_count":87,"is_preprint":false},{"pmid":"21352803","id":"PMC_21352803","title":"MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21352803","citation_count":86,"is_preprint":false},{"pmid":"27920253","id":"PMC_27920253","title":"Bmp Induces Osteoblast Differentiation through both Smad4 and mTORC1 Signaling.","date":"2017","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27920253","citation_count":83,"is_preprint":false},{"pmid":"25464861","id":"PMC_25464861","title":"SMAD4 and its role in pancreatic cancer.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25464861","citation_count":82,"is_preprint":false},{"pmid":"15014009","id":"PMC_15014009","title":"Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15014009","citation_count":81,"is_preprint":false},{"pmid":"32429474","id":"PMC_32429474","title":"SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32429474","citation_count":80,"is_preprint":false},{"pmid":"25753424","id":"PMC_25753424","title":"ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25753424","citation_count":77,"is_preprint":false},{"pmid":"10340387","id":"PMC_10340387","title":"DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10340387","citation_count":76,"is_preprint":false},{"pmid":"14597578","id":"PMC_14597578","title":"Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14597578","citation_count":75,"is_preprint":false},{"pmid":"31721429","id":"PMC_31721429","title":"Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein.","date":"2019","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31721429","citation_count":74,"is_preprint":false},{"pmid":"25373906","id":"PMC_25373906","title":"The tumor suppressor Smad4/DPC4 is regulated by phosphorylations that integrate FGF, Wnt, and TGF-β signaling.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25373906","citation_count":72,"is_preprint":false},{"pmid":"24739304","id":"PMC_24739304","title":"Follicle-stimulating hormone synthesis and fertility depend on SMAD4 and FOXL2.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24739304","citation_count":70,"is_preprint":false},{"pmid":"10398437","id":"PMC_10398437","title":"Frequent 4-bp deletion in exon 9 of the SMAD4/MADH4 gene in familial juvenile polyposis patients.","date":"1999","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10398437","citation_count":69,"is_preprint":false},{"pmid":"36991117","id":"PMC_36991117","title":"PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36991117","citation_count":68,"is_preprint":false},{"pmid":"29720405","id":"PMC_29720405","title":"Smad4/DPC4.","date":"2018","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29720405","citation_count":66,"is_preprint":false},{"pmid":"29986996","id":"PMC_29986996","title":"SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29986996","citation_count":66,"is_preprint":false},{"pmid":"38666907","id":"PMC_38666907","title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.","date":"2024","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38666907","citation_count":63,"is_preprint":false},{"pmid":"32415058","id":"PMC_32415058","title":"SMAD4 activates Wnt signaling pathway to inhibit granulosa cell apoptosis.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32415058","citation_count":62,"is_preprint":false},{"pmid":"31916354","id":"PMC_31916354","title":"Smad4 promotes diabetic nephropathy by modulating glycolysis and OXPHOS.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31916354","citation_count":60,"is_preprint":false},{"pmid":"9288786","id":"PMC_9288786","title":"Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9288786","citation_count":57,"is_preprint":false},{"pmid":"10698524","id":"PMC_10698524","title":"DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10698524","citation_count":56,"is_preprint":false},{"pmid":"10767528","id":"PMC_10767528","title":"Cloning and characterization of zebrafish smad2, smad3 and smad4.","date":"2000","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10767528","citation_count":53,"is_preprint":false},{"pmid":"30109253","id":"PMC_30109253","title":"Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer.","date":"2018","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30109253","citation_count":52,"is_preprint":false},{"pmid":"30664791","id":"PMC_30664791","title":"ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions.","date":"2019","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30664791","citation_count":51,"is_preprint":false},{"pmid":"28468752","id":"PMC_28468752","title":"USP4 inhibits SMAD4 monoubiquitination and promotes activin and BMP signaling.","date":"2017","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/28468752","citation_count":49,"is_preprint":false},{"pmid":"10436786","id":"PMC_10436786","title":"DPC4/SMAD4 gene alterations in human cancer, and their functional implications.","date":"1999","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10436786","citation_count":47,"is_preprint":false},{"pmid":"28160547","id":"PMC_28160547","title":"The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28160547","citation_count":47,"is_preprint":false},{"pmid":"35863523","id":"PMC_35863523","title":"SMAD4 Suppresses Colitis-associated Carcinoma Through Inhibition of CCL20/CCR6-mediated Inflammation.","date":"2022","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/35863523","citation_count":43,"is_preprint":false},{"pmid":"9155588","id":"PMC_9155588","title":"DPC4 gene mutation in colitis associated neoplasia.","date":"1997","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/9155588","citation_count":42,"is_preprint":false},{"pmid":"14669329","id":"PMC_14669329","title":"Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.","date":"2003","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/14669329","citation_count":42,"is_preprint":false},{"pmid":"10719364","id":"PMC_10719364","title":"Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers.","date":"2000","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10719364","citation_count":40,"is_preprint":false},{"pmid":"24715504","id":"PMC_24715504","title":"Novel SMAD4 mutation causing Myhre syndrome.","date":"2014","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/24715504","citation_count":40,"is_preprint":false},{"pmid":"34320363","id":"PMC_34320363","title":"SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34320363","citation_count":39,"is_preprint":false},{"pmid":"12622415","id":"PMC_12622415","title":"Smad4 transcriptional pathways and angiogenesis.","date":"2002","source":"International journal of gastrointestinal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12622415","citation_count":38,"is_preprint":false},{"pmid":"9862572","id":"PMC_9862572","title":"Smad4 (DPC4)--a potent tumour suppressor?","date":"1998","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9862572","citation_count":37,"is_preprint":false},{"pmid":"15573254","id":"PMC_15573254","title":"Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.","date":"2004","source":"World journal of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/15573254","citation_count":36,"is_preprint":false},{"pmid":"10993648","id":"PMC_10993648","title":"No SMAD4 hypermethylation in colorectal cancer.","date":"2000","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10993648","citation_count":35,"is_preprint":false},{"pmid":"34549820","id":"PMC_34549820","title":"Molecular diversity of diencephalic astrocytes reveals adult astrogenesis regulated by Smad4.","date":"2021","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/34549820","citation_count":32,"is_preprint":false},{"pmid":"25523394","id":"PMC_25523394","title":"Tak1, Smad4 and Trim33 redundantly mediate TGF-β3 signaling during palate development.","date":"2014","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25523394","citation_count":32,"is_preprint":false},{"pmid":"30410607","id":"PMC_30410607","title":"Roles of Smads Family and Alternative Splicing Variants of Smad4 in Different Cancers.","date":"2018","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30410607","citation_count":31,"is_preprint":false},{"pmid":"10871368","id":"PMC_10871368","title":"Functional mapping of the MH1 DNA-binding domain of DPC4/SMAD4.","date":"2000","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10871368","citation_count":31,"is_preprint":false},{"pmid":"10706106","id":"PMC_10706106","title":"A novel SMAD4 gene mutation in seminoma germ cell tumors.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10706106","citation_count":30,"is_preprint":false},{"pmid":"38103553","id":"PMC_38103553","title":"Smad4 sequestered in SFPQ condensates prevents TGF-β tumor-suppressive signaling.","date":"2023","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/38103553","citation_count":29,"is_preprint":false},{"pmid":"10708962","id":"PMC_10708962","title":"Gastro-intestinal tumorigenesis in Smad4 mutant mice.","date":"2000","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10708962","citation_count":28,"is_preprint":false},{"pmid":"30809044","id":"PMC_30809044","title":"SMAD4 rare variants in individuals and families with thoracic aortic aneurysms and dissections.","date":"2019","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/30809044","citation_count":28,"is_preprint":false},{"pmid":"10415848","id":"PMC_10415848","title":"Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle.","date":"1999","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10415848","citation_count":27,"is_preprint":false},{"pmid":"10408907","id":"PMC_10408907","title":"Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas.","date":"1999","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/10408907","citation_count":27,"is_preprint":false},{"pmid":"33888990","id":"PMC_33888990","title":"Consequences of Mutations and Abnormal Expression of SMAD4 in Tumors and T Cells.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33888990","citation_count":26,"is_preprint":false},{"pmid":"32103600","id":"PMC_32103600","title":"Wip1 regulates Smad4 phosphorylation and inhibits TGF-β signaling.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32103600","citation_count":26,"is_preprint":false},{"pmid":"10451707","id":"PMC_10451707","title":"Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovarian cancers.","date":"1999","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10451707","citation_count":26,"is_preprint":false},{"pmid":"11159190","id":"PMC_11159190","title":"Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11159190","citation_count":24,"is_preprint":false},{"pmid":"21492476","id":"PMC_21492476","title":"Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3ε.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21492476","citation_count":24,"is_preprint":false},{"pmid":"31167348","id":"PMC_31167348","title":"Smad4 Feedback Enhances BMPR1B Transcription in Ovine Granulosa Cells.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31167348","citation_count":24,"is_preprint":false},{"pmid":"25711193","id":"PMC_25711193","title":"Smad1/5 and Smad4 expression are important for osteoclast differentiation.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25711193","citation_count":23,"is_preprint":false},{"pmid":"11304690","id":"PMC_11304690","title":"Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11304690","citation_count":23,"is_preprint":false},{"pmid":"11172591","id":"PMC_11172591","title":"Somatic alterations of the DPC4 and Madr2 genes in colorectal cancers and relationship to metastasis.","date":"2001","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11172591","citation_count":23,"is_preprint":false},{"pmid":"34453124","id":"PMC_34453124","title":"SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34453124","citation_count":22,"is_preprint":false},{"pmid":"14647445","id":"PMC_14647445","title":"Loss of chromosome 18q and DPC4 (Smad4) mutations in appendiceal adenocarcinomas.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14647445","citation_count":22,"is_preprint":false},{"pmid":"26171675","id":"PMC_26171675","title":"Somatic alterations in juvenile polyps from BMPR1A and SMAD4 mutation carriers.","date":"2015","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26171675","citation_count":22,"is_preprint":false},{"pmid":"19841540","id":"PMC_19841540","title":"Smad4: gatekeeper gene in head and neck squamous cell carcinoma.","date":"2009","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19841540","citation_count":21,"is_preprint":false},{"pmid":"16082587","id":"PMC_16082587","title":"Analysis of SMAD4/DPC4 gene alterations in multiploid colorectal carcinomas.","date":"2005","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16082587","citation_count":21,"is_preprint":false},{"pmid":"18505344","id":"PMC_18505344","title":"Expression of DPC4/Smad4 in non-small-cell lung carcinoma and its relationship with angiogenesis.","date":"2008","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/18505344","citation_count":20,"is_preprint":false},{"pmid":"31684910","id":"PMC_31684910","title":"SMAD4 Y353C promotes the progression of PDAC.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31684910","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47248,"output_tokens":8277,"usd":0.132949,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18030,"output_tokens":7007,"usd":0.132662,"stage2_stop_reason":"end_turn"},"total_usd":0.265611,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"DPC4/SMAD4 was identified as a candidate tumor suppressor gene at chromosome 18q21.1, with homozygous deletions in ~30% and intragenic mutations in ~20% of pancreatic carcinomas, implicating it in a TGF-β-like signaling pathway based on sequence similarity to Drosophila Mad.\",\n      \"method\": \"Homozygous deletion mapping, PCR/sequencing of tumor DNA\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genomic mapping with convergent homozygous deletions and intragenic mutations across 84 tumors; founding paper replicated across many subsequent studies\",\n      \"pmids\": [\"8553070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"DPC4/SMAD4 physically associates with Smad1 in response to BMP and with Smad2 in response to activin or TGF-β, forming regulated heteromeric complexes essential for mesoderm induction and antimitogenic responses in Xenopus embryos and breast epithelial cells.\",\n      \"method\": \"Co-immunoprecipitation, Xenopus embryo overexpression/dominant-negative assays, mammalian cell TGF-β response assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus functional rescue in two distinct systems (Xenopus and mammalian cells); replicated by multiple subsequent studies\",\n      \"pmids\": [\"8893010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Smad4 is present in the activin-responsive factor (ARF) complex together with FAST-1 and Smad2; Smad4 stabilizes a ligand-stimulated Smad2-FAST-1 complex as an active DNA-binding factor. The FAST-1 C-terminal domain interacts with Smad2 (not Smad4 directly in yeast two-hybrid), but FAST-1 deletion mutants that cannot recruit Smad4 fail to associate with ARF.\",\n      \"method\": \"Co-immunoprecipitation (ligand-regulated), yeast two-hybrid, deletion mutagenesis, DNA-binding assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reciprocal Co-IP, yeast two-hybrid, and deletion mutagenesis in single study with multiple orthogonal methods\",\n      \"pmids\": [\"9288972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Smad4 contributes two distinct functions in TGF-β transcriptional complexes: its N-terminal (MH1) domain promotes DNA binding of the Smad2/Smad4/FAST-1 complex, while its C-terminal (MH2) domain provides a transcriptional activation function required for Smad1 or Smad2 to stimulate transcription. Smad4 is not required for nuclear translocation of Smad1/2 or for Smad2-FAST-1 association.\",\n      \"method\": \"Domain deletion and chimera constructs, transcriptional reporter assays, nuclear localization assays in mammalian cells\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — domain mapping with multiple deletion/chimera constructs plus functional transcriptional assays in single rigorous study\",\n      \"pmids\": [\"9389648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Smad3 and Smad4/DPC4 undergo both homomeric and heteromeric interactions via their conserved C-terminal (MH2) domains; Smad4 homomeric interaction additionally requires the N-terminal domain. Cancer-associated mutations in the MH2 domain impair homo- and heteromeric associations and correlate with reduced signaling activity.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, transcriptional activation assays in yeast and mammalian cells, analysis of tumor-derived mutations\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — yeast two-hybrid plus co-IP plus functional assays with multiple mutants; single lab with orthogonal methods\",\n      \"pmids\": [\"9111321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Smad4/DPC4 and CBP/p300 act as transcriptional coactivators for Smad3 in TGF-β-induced transcriptional activation; CBP associates with the C-terminus of Smad3 in a TGF-β-dependent manner, and this interaction requires Smad4. E1A expression, which blocks CBP function, inhibits TGF-β-induced transcription.\",\n      \"method\": \"Co-immunoprecipitation, transcriptional reporter assays, E1A inhibition experiments\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and functional transcriptional assays with multiple orthogonal approaches in single study\",\n      \"pmids\": [\"9679060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"A 47-amino acid deletion within the middle-linker region of Smad4 abolishes its ability to mediate TGF-β/activin signaling responses, while the N-terminal domain augments ligand-dependent activation, identifying a distinct ligand-response domain in the Smad4 linker.\",\n      \"method\": \"Smad4 deletion/chimera constructs, transcriptional reporter assays in Smad4-null cell line\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro functional domain mapping with multiple constructs but single lab, single study\",\n      \"pmids\": [\"9153220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Homozygous Smad4 knockout mice die before embryonic day 7.5 and fail to gastrulate or form mesoderm. Tetraploid rescue experiments demonstrated that the gastrulation defect is non-cell-autonomous, arising secondary to abnormal visceral endoderm differentiation.\",\n      \"method\": \"Homologous recombination knockout, tetraploid aggregation rescue, histological and molecular marker analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with tetraploid rescue (orthogonal method), mesodermal marker analysis; independently replicated by Yang et al. 1998\",\n      \"pmids\": [\"9420335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SMAD4 (truncating the C-terminal MH2 domain) homozygous knockout mice fail to undergo endoderm differentiation and mesoderm formation; blastocyst outgrowths show cellular proliferation defects, demonstrating that SMAD4-mediated signals are required for epiblast proliferation, egg-cylinder formation, and mesoderm induction.\",\n      \"method\": \"Homologous recombination knockout (exon 8 truncation), blastocyst outgrowth culture, histological and molecular marker analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — independent replication of Smad4 knockout phenotype with distinct targeting strategy; replicated Sirard et al. findings\",\n      \"pmids\": [\"9520423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"DPC4/SMAD4 restoration in DPC4-deleted breast tumor cells (MDA-MB-468) reconstitutes TGF-β1-induced growth inhibition and transcriptional activation of a TGF-β sensitive reporter (3TPlux). A DPC4 splice variant lacking residues 223–301 fails to restore TGF-β responsiveness.\",\n      \"method\": \"Transfection/reconstitution in Smad4-null cell line, growth inhibition assays, transcriptional reporter assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reconstitution plus splice-variant characterization in Smad4-null cells; single lab, two orthogonal readouts\",\n      \"pmids\": [\"9150356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Alanine-scanning mutagenesis of the MH1 domain mapped DNA-binding activity to residues L43–R135, demonstrating that the MH1 domain as a whole is structurally sensitive and that tumor-associated mutations outside the beta-hairpin motif inactivate Smad4 by disrupting DNA binding.\",\n      \"method\": \"Alanine scanning mutagenesis (20 individual mutations), in vitro DNA-binding assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic in vitro mutagenesis with DNA-binding assay; multiple mutants tested in single rigorous study\",\n      \"pmids\": [\"10871368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Restoration of Smad4 in pancreatic carcinoma cells suppressed tumor formation in vivo without restoring TGF-β sensitivity; instead, Smad4 shifted angiogenic balance by decreasing VEGF expression and increasing thrombospondin-1 expression, reducing vascular density in tumors.\",\n      \"method\": \"Stable reconstitution in Smad4-null pancreatic cancer cells, in vivo nude mouse tumor assays, VEGF/thrombospondin-1 expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution plus in vivo assay plus molecular target identification; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"10944227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In SW480.7 colon cancer cells, Smad4 loss is due to epigenetic silencing (not mutation); conditional re-expression of Smad4 alone failed to rescue TGF-β antiproliferative responses because co-existing hyperactive Ki-Ras inhibits Smad nuclear accumulation via MAPK phosphorylation. Co-expression of Smad4 with a Ras-phosphorylation-resistant Smad3 (but not wild-type Smad2, Smad3, APC, or TGF-β type II receptor) rescued the antiproliferative response.\",\n      \"method\": \"Ecdysone-inducible Smad4 expression, co-transfection epistasis analysis, cell proliferation assays, p21/c-myc gene response assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via co-transfection with multiple constructs plus functional proliferation readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"10559252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SCF(β-TrCP1) ubiquitin E3 ligase interacts with Smad4 (but not Smad2, and only indirectly with Smad3 through Smad4) and promotes Smad4 ubiquitination and proteasomal degradation; ectopic SCF(β-TrCP1) inhibited TGF-β-dependent transcriptional activity and cell cycle arrest, while siRNA knockdown of β-TrCP1 increased Smad4 protein levels.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, ubiquitination assays, siRNA knockdown, transcriptional reporter assays, cell cycle assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods including yeast two-hybrid, Co-IP, ubiquitination assay, siRNA, and functional readouts in single study\",\n      \"pmids\": [\"14988407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Smad4 activity is directly regulated by phosphorylation: FGF activates MAPK which primes three sequential GSK3 phosphorylations in the Smad4 linker region, generating a β-TrCP-bound phosphodegron. Wnt signaling prevents these GSK3 phosphorylations and thereby potentiates TGF-β/Smad4 transcriptional activity. These phosphorylations regulate germ-layer specification in Xenopus embryos.\",\n      \"method\": \"Phosphosite mutagenesis, kinase assays (MAPK, GSK3), Xenopus embryo gain/loss-of-function experiments, β-TrCP binding assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — kinase assays, mutagenesis, and in vivo Xenopus validation with multiple orthogonal approaches in single study\",\n      \"pmids\": [\"25373906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ALK tyrosine kinase directly phosphorylates SMAD4 at Tyr95; phospho-Y95 SMAD4 cannot bind DNA and fails to elicit TGF-β gene responses or tumor-suppressive responses. Chemical or genetic inhibition of ALK restores TGF-β responses in ALK-positive tumor cells.\",\n      \"method\": \"In vitro kinase assay, phospho-specific antibody, DNA-binding assay, transcriptional reporter assays, ALK inhibitor treatment and genetic knockdown\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase reconstitution plus mutagenesis plus functional DNA-binding and transcriptional readouts with pharmacological and genetic validation\",\n      \"pmids\": [\"30664791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"USP4 deubiquitinase removes inhibitory monoubiquitination from SMAD4, sustaining its activity in activin/BMP signaling. SMURF2 E3 ligase is recruited to SMAD4 upon ligand-induced R-SMAD-SMAD4 complex formation to add monoubiquitin. The negative regulator c-SKI inhibits SMAD4 monoubiquitination. USP4 depletion in mouse ESCs increased monoubiquitinated SMAD4 and impaired BMP/activin-induced cell fate changes.\",\n      \"method\": \"Ubiquitination assays, co-immunoprecipitation, USP4 knockdown in mouse ESCs, zebrafish morpholino knockdown with rescue experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — biochemical ubiquitination assays plus genetic loss-of-function in ESCs and zebrafish with functional rescue; multiple orthogonal methods\",\n      \"pmids\": [\"28468752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"USP10 deubiquitinase directly interacts with Smad4 and stabilizes it by removing proteolytic ubiquitination, thereby activating TGF-β signaling and promoting HCC metastasis. Suppression of USP10 reduced Smad4 protein levels and inhibited HCC cell migration; reconstitution of Smad4 rescued this defect.\",\n      \"method\": \"siRNA library screen, co-immunoprecipitation, ubiquitination assays, shRNA knockdown, Smad4 reconstitution, migration assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional screen plus Co-IP plus ubiquitination assay plus rescue experiment; single lab, multiple methods\",\n      \"pmids\": [\"31721429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Wip1 phosphatase selectively binds and dephosphorylates Smad4 at Thr277 (a key MAPK phosphorylation site), regulating Smad4 nuclear accumulation and protein half-life. Wip1 restrains TGF-β-induced growth arrest, migration, and invasion, and inhibits Smad4 antimitogenic activity in human cells and mesoderm formation in Xenopus.\",\n      \"method\": \"Co-immunoprecipitation, phosphatase assay, phospho-specific antibody detection, Xenopus gain/loss-of-function, cell migration/invasion assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical phosphatase assay plus Co-IP plus in vivo Xenopus validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32103600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT5 interacts with SMAD4 under TGF-β1 treatment and methylates SMAD4 at R361; this methylation is required for SMAD complex formation and nuclear import. SMAD4 R361 mutation abolishes PRMT5-induced EMT and colorectal cancer metastasis.\",\n      \"method\": \"Mass spectrometry, co-immunoprecipitation, immunofluorescence, methylation-specific assays, SMAD4 R361 mutant functional studies\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry identification plus Co-IP plus functional mutagenesis; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36991117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SFPQ, a prion-like RNA-binding protein, physically sequesters Smad4 in liquid-liquid phase separation (LLPS) condensates via its prion-like domain (PrLD), excluding Smad4 from Smad complexes and chromatin, thereby suppressing TGF-β transcriptional responses. SFPQ deficiency or abolition of phase separation activity renders cells hypersensitive to TGF-β.\",\n      \"method\": \"Co-immunoprecipitation, LLPS assays, ChIP, transcriptional reporter assays, SFPQ phase-separation mutants\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical LLPS characterization plus Co-IP plus chromatin occupancy assays; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38103553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Endothelial-specific loss of Smad4 in mice causes arteriovenous malformation (AVM) formation. Mechanistically, BMP9 signaling antagonizes flow-induced AKT activation in an ALK1- and SMAD4-dependent manner; Smad4-deficient endothelial cells display increased PI3K/AKT signaling. BMP9-induced SMAD4 inhibits CK2 (casein kinase 2) transcription, limiting PTEN phosphorylation and AKT activation. PI3K inhibition or endothelial Akt1 deletion rescues AVMs in Smad4-deficient mice.\",\n      \"method\": \"Tamoxifen-inducible endothelial-specific Smad4 knockout mice, pharmacological PI3K inhibition, Akt1 genetic rescue, CK2 inhibition, AKT phosphorylation assays\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional knockout with multiple genetic and pharmacological rescue experiments; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"29976569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMAD4 and HNF4 (HNF4A and HNF4G) function via a reinforcing feed-forward loop in the intestinal epithelium: SMAD4 and HNF4 activate each other's expression and co-bind regulatory elements of differentiation genes to promote and stabilize enterocyte cell identity. Disruption of this HNF4-SMAD4 module results in loss of enterocyte fate in favor of progenitor and secretory cell lineages.\",\n      \"method\": \"Conditional double knockout (HNF4A/G), SMAD4 conditional knockout, ChIP-seq cistromic analysis, transcriptomic profiling, intestinal organoid assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — combined genetic knockout with ChIP-seq co-binding data and transcriptomics; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30988513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SMAD4 is absolutely required for normal FSH (Fshb) synthesis in vivo; conditional Smad4 deletion in gonadotropes abolishes FSH synthesis. Combined deletion of Smad4 and its DNA-binding cofactor FOXL2 in gonadotropes results in near-complete absence of FSH and female sterility, phenocopying Fshb-knockout mice, establishing SMAD4 and FOXL2 as essential co-regulators of Fshb transcription.\",\n      \"method\": \"Conditional gonadotrope-specific Smad4 and Foxl2 single/double knockout mice, FSH measurement, fertility assessment\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean conditional knockout with quantitative FSH measurement and genetic epistasis; single lab, multiple knockout combinations\",\n      \"pmids\": [\"24739304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Under hyperglycemic conditions, Smad4 localizes to mitochondria in podocytes, directly binds the glycolytic enzyme PKM2 (reducing its active tetrameric form) and interacts with ATPIF1 (reducing its degradation), resulting in reduced glycolysis and oxidative phosphorylation and increased ROS production, contributing to diabetic nephropathy.\",\n      \"method\": \"Conditional podocyte-specific Smad4 knockout mice, subcellular fractionation, co-immunoprecipitation, PKM2 activity assays, metabolic flux measurements\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional knockout plus Co-IP plus enzymatic activity assay; single lab with multiple methods but novel/unusual finding\",\n      \"pmids\": [\"31916354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mammary epithelium-specific Smad4 deletion causes squamous cell carcinoma and mammary abscesses via transdifferentiation. Loss of Smad4 leads to β-catenin accumulation at onset of transdifferentiation; TGF-β1 degrades β-catenin in cultured mammary epithelial cells, but this action is blocked in the absence of Smad4, implicating Smad4 in suppressing Wnt/β-catenin signaling during cell fate maintenance.\",\n      \"method\": \"Cre-loxP conditional mammary-specific Smad4 knockout, immunohistochemistry for β-catenin, TGF-β1 treatment assays in cultured cells\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional knockout plus mechanistic cell culture validation; single lab with multiple approaches\",\n      \"pmids\": [\"14597578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SMAD4 represses FOSL1 expression; in pancreatic cancer cells, SMAD4 loss leads to FOSL1 upregulation that is sufficient to drive metastatic colonization to the lung, identified by an in vivo CRISPR/genetic screen.\",\n      \"method\": \"Isogenic cell lines with/without SMAD4, in vivo functional screen, transcriptomic analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo screen plus isogenic cell comparison; single lab, functional validation limited to screen confirmation\",\n      \"pmids\": [\"34320363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"DPC4 inactivation in pancreatic cancer occurs late in neoplastic progression: all PanIN-1A, PanIN-1B, and PanIN-2 lesions retained Dpc4 expression, while 31% of PanIN-3 (carcinoma in situ) lesions lost it, demonstrating stage-specific loss of the tumor suppressor.\",\n      \"method\": \"Immunohistochemistry for Dpc4 protein in 188 pancreatic intraepithelial neoplasias (PanINs) correlated with genetic status\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic IHC correlated with genetic status across large series; replicated across multiple pancreatic cancer studies\",\n      \"pmids\": [\"10766191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Missense mutations in SMAD4 are concentrated in the MH2 domain (77%), with a mutation cluster region (MCR) at codons 330–370. Mutations outside the MCR correlate with loss of Madh4 protein (suggesting degradation), while MCR mutations retain nuclear protein, indicating that most missense mutations inactivate Smad4 via protein destabilization/degradation rather than direct functional disruption.\",\n      \"method\": \"Sequence analysis of tumors, immunohistochemistry for Madh4 protein in archival cancers with known missense mutations\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — systematic mutation mapping with IHC correlation across multiple tumor types; functional inference from protein expression pattern\",\n      \"pmids\": [\"15014009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Combined loss of PTEN and SMAD4 in mouse airway epithelium leads to metastatic adenosquamous lung tumors through ELF3 and ErbB2 pathway activation due to decreased ERRFI1 expression. Combinatorial inhibition of ErbB2 and Akt attenuates tumor progression and invasion.\",\n      \"method\": \"Conditional Pten/Smad4 double knockout mouse model, comparative transcriptomics, in vivo cistromics, pharmacological inhibition\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double conditional knockout with transcriptomic and cistromic analysis plus pharmacological rescue; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"25753424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMAD4 directly binds the FZD4 promoter as a transcription factor to activate FZD4 transcription in granulosa cells, and also promotes FZD4 expression indirectly via induction of a lncRNA (SDNOR) that sponges miR-29c (which would otherwise degrade FZD4 mRNA), establishing a SMAD4-FZD4 axis that activates Wnt signaling to regulate granulosa cell apoptosis.\",\n      \"method\": \"ChIP (SMAD4 binding to FZD4 promoter), luciferase reporter assays, SMAD4 overexpression/knockdown, miRNA sponge assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus luciferase plus functional knockdown; single lab with multiple methods\",\n      \"pmids\": [\"32415058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Smad4 regulates adult astrocyte proliferation in the diencephalon; Smad4 deletion in diencephalic astrocytes reduces in vivo proliferation and in vitro neurosphere formation, identifying Smad4 as a key regulator of adult astrogenesis in this brain region.\",\n      \"method\": \"Single-cell RNA-seq, MACS isolation of astrocytes, conditional Smad4 deletion, BrdU/clonal analysis, neurosphere assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional knockout with in vivo clonal analysis and in vitro neurosphere assay; single lab, multiple methods\",\n      \"pmids\": [\"34549820\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMAD4/DPC4 functions as the central co-SMAD in TGF-β superfamily signaling: upon ligand stimulation, it forms heteromeric complexes with receptor-activated SMADs (R-SMADs such as Smad1, Smad2, Smad3), translocates to the nucleus, and activates transcription via its MH1 DNA-binding domain and MH2 transcriptional activation domain, in cooperation with co-activators such as CBP/p300 and transcription factors such as FAST-1, HNF4, and FOXL2; its activity is dynamically regulated by multiple post-translational modifications including GSK3/MAPK-primed phosphodegron formation (targeting it for SCF(β-TrCP1)-mediated ubiquitin-proteasomal degradation), SMURF2-mediated inhibitory monoubiquitination (reversed by USP4 and USP10 deubiquitinases), Wip1-mediated Thr277 dephosphorylation, PRMT5-mediated R361 methylation (required for SMAD complex assembly), and ALK-mediated Y95 phosphorylation (which blocks DNA binding); SFPQ can sequester SMAD4 in phase-separated condensates to suppress its transcriptional activity; in addition to canonical transcriptional roles, SMAD4 suppresses angiogenesis (by decreasing VEGF and increasing thrombospondin-1), regulates the PI3K/AKT/CK2 axis in endothelium to prevent arteriovenous malformations, and controls intestinal differentiation via a reinforcing feed-forward loop with HNF4, while its loss in various epithelial contexts promotes tumor progression through de-repression of VEGF, FOSL1, CCL20, and WNT/β-catenin-driven dedifferentiation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMAD4 (DPC4) is the central co-SMAD that transduces TGF-β superfamily signals into transcriptional responses and acts as a tumor suppressor first identified through homozygous deletion and intragenic mutation at chromosome 18q21.1 in pancreatic carcinoma [#0]. Upon ligand stimulation it forms regulated heteromeric complexes with receptor-activated R-SMADs — Smad1 in response to BMP and Smad2 in response to activin/TGF-β — interactions that drive mesoderm induction and antimitogenic responses [#1]. Within these complexes SMAD4 contributes two separable functions: its N-terminal MH1 domain promotes DNA binding while its C-terminal MH2 domain supplies a transcriptional activation function, with the MH2 domain also mediating the homo- and heteromeric associations that cancer-associated mutations disrupt [#3, #4, #10]. SMAD4 stabilizes DNA-binding transcription-factor complexes (e.g., the Smad2–FAST-1 ARF complex) and recruits the coactivator CBP/p300 to activate TGF-β-responsive transcription [#2, #5]. Genetically it is essential for early development, as Smad4-null mice fail to gastrulate and form mesoderm owing to defective visceral endoderm and epiblast proliferation [#7, #8]. SMAD4 activity is tuned by a dense layer of post-translational control: MAPK/GSK3-primed linker phosphorylation generates a β-TrCP phosphodegron targeting SMAD4 for SCF(β-TrCP1)-mediated proteasomal degradation [#13, #14]; SMURF2-mediated inhibitory monoubiquitination is reversed by the deubiquitinases USP4 and USP10 [#16, #17]; Wip1 dephosphorylates Thr277 to limit nuclear accumulation [#18]; PRMT5-mediated R361 methylation is required for SMAD complex assembly and nuclear import [#19]; ALK-mediated Tyr95 phosphorylation blocks DNA binding [#15]; and SFPQ sequesters SMAD4 in phase-separated condensates to exclude it from chromatin [#20]. Beyond canonical transcription, SMAD4 enforces tissue identity and suppresses tumor progression — shifting the angiogenic balance by repressing VEGF and inducing thrombospondin-1 [#11], restraining endothelial PI3K/AKT signaling through CK2 to prevent arteriovenous malformations [#21], stabilizing enterocyte identity via a reinforcing feed-forward loop with HNF4 [#22], and suppressing Wnt/β-catenin-driven dedifferentiation and metastatic effectors such as FOSL1 [#25, #26]. Germline/somatic loss in epithelial contexts thus de-represses pro-tumorigenic programs, with DPC4 inactivation occurring late in pancreatic neoplastic progression [#27].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established SMAD4/DPC4 as a candidate tumor suppressor and placed it in a TGF-β-like pathway, answering where the gene sits in cancer genetics.\",\n      \"evidence\": \"Homozygous deletion mapping and sequencing of pancreatic tumor DNA at 18q21.1\",\n      \"pmids\": [\"8553070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the biochemical activity of the protein\", \"Pathway link inferred from sequence similarity to Mad rather than direct biochemistry\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined SMAD4 as a ligand-regulated partner of multiple R-SMADs, answering how it couples to distinct TGF-β superfamily ligands.\",\n      \"evidence\": \"Co-immunoprecipitation plus Xenopus and mammalian functional assays\",\n      \"pmids\": [\"8893010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map the domains mediating each interaction\", \"Did not establish nuclear vs cytoplasmic site of complex assembly\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved the molecular logic of SMAD4 within transcriptional complexes — MH1 for DNA binding, MH2 for activation and oligomerization — explaining why cancer mutations cluster in MH2.\",\n      \"evidence\": \"Domain deletion/chimera constructs, yeast two-hybrid, ARF complex reconstitution, reporter assays\",\n      \"pmids\": [\"9288972\", \"9389648\", \"9111321\", \"9153220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional contribution of the linker region characterized in only a single study\", \"Did not provide atomic structure of the complexes\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated that SMAD4 re-expression restores TGF-β growth inhibition in SMAD4-null tumor cells, establishing causal tumor-suppressive function.\",\n      \"evidence\": \"Reconstitution in MDA-MB-468 cells with growth inhibition and reporter readouts\",\n      \"pmids\": [\"9150356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line\", \"Did not separate growth-arrest from later angiogenic functions\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed SMAD4 is essential for gastrulation and mesoderm formation, defining its non-redundant developmental requirement.\",\n      \"evidence\": \"Two independent knockout mouse lines with tetraploid rescue and blastocyst outgrowth analysis\",\n      \"pmids\": [\"9420335\", \"9520423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lethality precludes analysis of later tissue-specific roles\", \"Did not identify the downstream developmental targets\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified CBP/p300 as the coactivator SMAD4 recruits, answering how the complex drives transcription.\",\n      \"evidence\": \"Co-IP, reporter assays, and E1A inhibition\",\n      \"pmids\": [\"9679060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map promoter-specific recruitment\", \"Did not address coactivator competition in vivo\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed a transcription-independent tumor-suppressive output — angiogenesis suppression via VEGF down and thrombospondin-1 up — broadening SMAD4 function beyond growth arrest.\",\n      \"evidence\": \"Stable reconstitution in pancreatic cancer cells with in vivo nude-mouse tumor and expression analysis\",\n      \"pmids\": [\"10944227\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of VEGF/TSP-1 regulation not resolved at promoter level\", \"Restoration occurred without restoring TGF-β sensitivity\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapped MH1 DNA-binding determinants and showed tumor mutations inactivate SMAD4 by disrupting DNA binding or protein stability, linking genotype to molecular defect.\",\n      \"evidence\": \"Alanine-scanning mutagenesis with in vitro DNA-binding assays; later IHC mutation mapping\",\n      \"pmids\": [\"10871368\", \"15014009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stability-based inactivation is inferred from protein levels rather than direct turnover measurement\", \"MH1 mutation effects assessed in vitro\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Established the timing of DPC4 loss in pancreatic neoplasia, answering when in tumor evolution the suppressor is inactivated.\",\n      \"evidence\": \"IHC across 188 PanIN lesions correlated with genetic status\",\n      \"pmids\": [\"10766191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Correlative; does not prove loss drives progression\", \"Restricted to pancreatic lesions\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed that SMAD4 maintains epithelial identity by suppressing Wnt/β-catenin, explaining transdifferentiation phenotypes upon loss.\",\n      \"evidence\": \"Mammary-specific conditional knockout with β-catenin IHC and TGF-β1 degradation assays\",\n      \"pmids\": [\"14597578\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking SMAD4 to β-catenin degradation not biochemically defined\", \"Single tissue context\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified SCF(β-TrCP1) as a SMAD4 E3 ligase, establishing proteasomal control of SMAD4 abundance and signaling output.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, ubiquitination assays, siRNA, functional readouts\",\n      \"pmids\": [\"14988407\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the degron recognized by β-TrCP\", \"Upstream priming kinases unidentified at this stage\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the MAPK/GSK3-primed phosphodegron and its antagonism by Wnt, integrating SMAD4 stability into broader signaling crosstalk.\",\n      \"evidence\": \"Phosphosite mutagenesis, kinase assays, β-TrCP binding, Xenopus gain/loss-of-function\",\n      \"pmids\": [\"25373906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance shown in Xenopus; mammalian developmental role not addressed\", \"Did not quantify endogenous degradation kinetics\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated an essential SMAD4–FOXL2 partnership for FSH synthesis, establishing a tissue-specific transcriptional cofactor relationship.\",\n      \"evidence\": \"Gonadotrope-specific single and double conditional knockouts with FSH and fertility measurement\",\n      \"pmids\": [\"24739304\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct co-occupancy of the Fshb promoter not shown here\", \"Limited to gonadotrope lineage\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed SMAD4 loss cooperates with PTEN loss to drive metastatic lung tumors via ERRFI1/ErbB2 signaling, expanding its suppressor function to a new epithelium.\",\n      \"evidence\": \"Pten/Smad4 double knockout mice with transcriptomics, cistromics, pharmacological inhibition\",\n      \"pmids\": [\"25753424\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Combinatorial context required; single-gene SMAD4 effect not isolated\", \"Direct SMAD4 regulation of ERRFI1 not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established that reversible SMURF2 monoubiquitination, opposed by USP4, tunes SMAD4 activity in stem-cell fate decisions.\",\n      \"evidence\": \"Ubiquitination assays, Co-IP, USP4 knockdown in ESCs, zebrafish morpholino rescue\",\n      \"pmids\": [\"28468752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Monoubiquitination site on SMAD4 not specified here\", \"Interplay with degradative ubiquitination not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined an endothelial-specific SMAD4 function preventing arteriovenous malformations via BMP9/ALK1 restraint of PI3K/AKT through CK2, distinguishing a vascular role from canonical transcription.\",\n      \"evidence\": \"Endothelial-specific inducible knockout with PI3K inhibition, Akt1 deletion, and CK2 manipulation rescues\",\n      \"pmids\": [\"29976569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional repression of CK2 by SMAD4 inferred\", \"Human AVM relevance not tested in this study\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified ALK-mediated Tyr95 phosphorylation as a DNA-binding-blocking modification, providing a druggable route to restore SMAD4 tumor suppression.\",\n      \"evidence\": \"In vitro kinase assay, phospho-specific antibody, DNA-binding/reporter assays, ALK inhibition\",\n      \"pmids\": [\"30664791\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Prevalence of Y95 phosphorylation across tumor types not quantified\", \"Structural basis of DNA-binding loss not solved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed USP10 deubiquitinates and stabilizes SMAD4 to promote HCC metastasis, illustrating context-dependent oncogenic output of SMAD4 stabilization.\",\n      \"evidence\": \"siRNA screen, Co-IP, ubiquitination assays, knockdown with SMAD4 rescue, migration assays\",\n      \"pmids\": [\"31721429\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cancer context; reciprocal to suppressor role\", \"Ubiquitin linkage type not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a SMAD4–HNF4 feed-forward loop that stabilizes enterocyte identity, explaining how SMAD4 enforces lineage fate.\",\n      \"evidence\": \"Conditional knockouts, ChIP-seq co-binding, transcriptomics, organoid assays\",\n      \"pmids\": [\"30988513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address upstream ligand control of the loop\", \"Tumor-suppressive consequence in intestine not directly tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified a SMAD4–FZD4 axis (direct promoter binding plus lncRNA-mediated regulation) coupling SMAD4 to Wnt activation in granulosa cells.\",\n      \"evidence\": \"ChIP, luciferase, overexpression/knockdown, miRNA sponge assays\",\n      \"pmids\": [\"32415058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell-type context\", \"lncRNA/miR-29c module not validated in vivo\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed Wip1 dephosphorylates SMAD4 at Thr277 to restrain its nuclear accumulation and antimitogenic activity, adding phosphatase control to the regulatory layer.\",\n      \"evidence\": \"Co-IP, phosphatase assay, phospho-specific detection, Xenopus and migration/invasion assays\",\n      \"pmids\": [\"32103600\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Relationship of Thr277 to the GSK3/β-TrCP degron not integrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a non-transcriptional mitochondrial SMAD4 function binding PKM2 and ATPIF1 to alter metabolism in diabetic nephropathy.\",\n      \"evidence\": \"Podocyte-specific knockout, subcellular fractionation, Co-IP, enzyme activity and metabolic flux assays\",\n      \"pmids\": [\"31916354\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Unusual mitochondrial localization not independently confirmed\", \"Mechanism of SMAD4 mitochondrial import unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified FOSL1 de-repression as a sufficient driver of metastasis upon SMAD4 loss in pancreatic cancer.\",\n      \"evidence\": \"Isogenic SMAD4 cells, in vivo CRISPR/genetic screen, transcriptomics\",\n      \"pmids\": [\"34320363\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Validation limited to screen confirmation\", \"Direct vs indirect FOSL1 repression not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established SMAD4 as a regulator of adult astrocyte proliferation, extending its role to CNS lineage maintenance.\",\n      \"evidence\": \"scRNA-seq, conditional deletion, BrdU/clonal analysis, neurosphere assays\",\n      \"pmids\": [\"34549820\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream transcriptional program in astrocytes unknown\", \"Single brain region\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined PRMT5-mediated R361 methylation as a requirement for SMAD complex assembly and nuclear import, adding methylation to SMAD4 control and linking it to EMT/metastasis.\",\n      \"evidence\": \"Mass spectrometry, Co-IP, immunofluorescence, R361 mutant functional studies\",\n      \"pmids\": [\"36991117\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Interplay with phosphorylation/ubiquitination not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed SFPQ sequesters SMAD4 in phase-separated condensates to suppress its activity, introducing biomolecular condensation as a regulatory mechanism.\",\n      \"evidence\": \"Co-IP, LLPS assays, ChIP, reporter assays, SFPQ phase-separation mutants\",\n      \"pmids\": [\"38103553\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological/in vivo relevance of condensate sequestration not established\", \"Single study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the layered post-translational marks (phospho-degron, mono-ubiquitination, methylation, tyrosine phosphorylation) and condensate sequestration are coordinated to set SMAD4 output in a given tissue remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated model reconciling competing modifications\", \"Tissue-specific selectivity of regulators not mapped\", \"No structural model of the modified, complex-assembled SMAD4\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 10, 15, 30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 5, 22, 30]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 18, 19]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 14]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 5, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 8, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 11, 26]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [13, 16, 19]}\n    ],\n    \"complexes\": [\"SMAD2/SMAD4/FAST-1 (ARF) complex\", \"R-SMAD/SMAD4 heteromeric complex\"],\n    \"partners\": [\"SMAD2\", \"SMAD3\", \"SMAD1\", \"FAST-1\", \"CBP/p300\", \"HNF4A\", \"FOXL2\", \"SFPQ\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}